{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T14:45:15Z","timestamp":1766760315619},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.ijantimicag.2011.08.012","type":"journal-article","created":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T23:19:38Z","timestamp":1318547978000},"page":"474-479","source":"Crossref","is-referenced-by-count":11,"title":["Effect of telavancin on human intestinal microflora"],"prefix":"10.1016","volume":"38","author":[{"given":"Mamun-Ur","family":"Rashid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrej","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl Erik","family":"Nord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0005","series-title":"Antimicrobial agents","first-page":"1357","article-title":"Interaction between antimicrobial agents and the oropharyngeal and the intestinal microflora","author":"Sullivan","year":"2005"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0010","unstructured":"European Agency for the Evaluation of Medicinal Products. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. London, UK: EMEA; 2000. CPMP\/EWP\/2655\/99."},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1473-3099(01)00066-4","article-title":"Effect of antimicrobial agents on the ecological balance of human microflora","volume":"1","author":"Sullivan","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0020","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","article-title":"Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0025","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.01710-08","article-title":"Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II","volume":"53","author":"Lunde","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0030","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1086\/648438","article-title":"Telavancin: a novel lipoglycopeptide","volume":"49","author":"Saravolatz","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0035","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0045","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijantimicag.2010.07.021","article-title":"Effect of ceftobiprole on the normal human intestinal microflora","volume":"36","author":"Backstrom","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0050","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/jac\/dkl281","article-title":"Effect of dalbavancin on the normal intestinal microflora","volume":"58","author":"Nord","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0055","series-title":"Manual of clinical microbiology","author":"Murray","year":"2007"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0060","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1128\/JCM.01280-09","article-title":"Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of Clostridium difficile infections","volume":"47","author":"Huang","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0065","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006."},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0070","unstructured":"Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. 7th ed. Document M11-A7. Wayne, PA: CLSI; 2007."},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0075","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jac\/dkn124","article-title":"In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004\u201305 Prospective European Surveillance Initiative","volume":"62","author":"Draghi","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0080","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1128\/AAC.00908-08","article-title":"In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates","volume":"53","author":"Finegold","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0085","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.00301-10","article-title":"In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates","volume":"54","author":"Mendes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0090","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1128\/AAC.49.1.195-201.2005","article-title":"Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects","volume":"49","author":"Shaw","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0095","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1128\/AAC.01750-09","article-title":"Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers","volume":"54","author":"Shaw","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0100","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/jac\/dkn273","article-title":"Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects","volume":"62","author":"Wong","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0105","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2011.08.012_bib0110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0924-8579(00)00192-8","article-title":"The fluoroquinolone antibacterials: past, present and future perspectives","volume":"16","author":"Appelbaum","year":"2000","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. C","key":"10.1016\/j.ijantimicag.2011.08.012_bib0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/41.suppl_3.21","article-title":"The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease","volume":"41","author":"Spencer","year":"1998","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857911003578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857911003578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T10:28:01Z","timestamp":1543487281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857911003578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0924857911003578"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.08.012","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}